Recent Advances in HIV-1 Gag Inhibitor Design and Development.
Acquired Immune Deficiency Syndrome (AIDS) treatment with combination antiretroviral therapy (cART) has improved the life quality of many patients since its implementation. However, resistance mutations and the accumulation of severe side effects associated with cART remain enormous challenges that need to be addressed with the continual design and redesign of anti-HIV drugs. In this review, we focus on the importance of the HIV-1 Gag polyprotein as the master coordinator of HIV-1 assembly and maturation and as an emerging drug target. Due to its multiple roles in the HIV-1 life cycle, the individual Gag domains are attractive but also challenging targets for inhibitor design. However, recent encouraging developments in targeting the Gag domains such as the capsid protein with highly potent and potentially long-acting inhibitors, as well as the exploration and successful targeting of challenging HIV-1 proteins such as the matrix protein, have demonstrated the therapeutic viability of this important protein. Such Gag-directed inhibitors have great potential for combating the AIDS pandemic and to be useful tools to dissect HIV-1 biology.
['Dick|Alexej|A|', 'Cocklin|Simon|S|0000-0002-9074-741X']
D000163:Acquired Immunodeficiency Syndrome D019380:Anti-HIV Agents D036022:Capsid Proteins D024882:Drug Resistance, Viral D017320:HIV Protease Inhibitors D015497:HIV-1 D006801:Humans D054301:gag Gene Products, Human Immunodeficiency Virus
antiretrovirals HIV-1 Gag polyprotein capsid protein matrix protein nucleocapsid protein p6 protein